CJ Bioscience Partners with Sun Medical Center for Gut Microbiome Testing Collaboration

by Lee Sungmin

Published 30 Jan.2026 10:20(KST)

Development of Solutions Based on "GUT INSIDE"

On January 30, CJ Bioscience announced that it has signed a Memorandum of Understanding (MOU) with Sun Medical Center of Younghoon Medical Foundation to develop customized healthcare solutions based on the gut microbiome testing service "GUT INSIDE" and to promote related business initiatives.

CJ Bioscience and Sun Medical Center of Younghoon Medical Foundation have signed a Memorandum of Understanding (MOU) to develop customized healthcare solutions based on the gut microbiome testing service "GUT INSIDE" and to promote related business. From left: Eunsoon Kim, Director of Yuseong Sun Hospital; Guiheung Oh, Management Leader of CJ Bioscience; Sunwoo Nam, Director of Daejeon Sun Hospital. CJ Bioscience

With this MOU, the two organizations will collaborate across the entire business and operational spectrum of the gut microbiome testing service, jointly planning healthcare solutions for diagnosis, treatment, and overall health management utilizing the service. They plan to gradually expand mutually agreed-upon collaborative projects, including the use of data for research and validation purposes. CJ Bioscience will provide its gut microbiome analysis technology and solution development capabilities, while Sun Medical Center will be responsible for operating the testing service in clinical settings, conducting research and validation, and providing related data.

This partnership is significant in that it will accumulate case studies by linking the gut microbiome testing service to clinical practice and assess its potential applications in medical settings. Through this, the companies aim to gradually expand the effectiveness and application scope of the GUT INSIDE gut microbiome-based healthcare solution.

GUT INSIDE is a personalized healthcare service based on gut microbiome analysis. It analyzes the DNA of gut microbes in stool samples using next-generation sequencing (NGS) technology to provide key indicators such as the Gut Microbiome Index (GMI), gut types, and microbial diversity. Artificial intelligence (AI) analysis based on data from healthy and disease groups enables quantitative assessment of gut environment-related information.

A CJ Bioscience official stated, "We will gradually advance the service and expand our business based on experience and data from clinical environments."